Global Bio-engineered Stent Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Drug-Eluting Stents, Bioabsorbable Stents, and Drug Eluting Balloons

By Mode of Delivery;

Balloon-Expandable Stents and Self-Expanding Stents

By Material;

Metal-Based and Polymer-Based

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn134129439 Published Date: June, 2025 Updated Date: July, 2025

Bio-engineered Stent Market Overview

Bio-engineered Stent Market (USD Million)

Bio-engineered Stent Market was valued at USD 3,120.04 million in the year 2024. The size of this market is expected to increase to USD 4,993.74 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Global Bio-engineered Stent Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 3,120.04 Million
Market Size (2031)USD 4,993.74 Million
Market ConcentrationMedium
Report Pages326
3,120.04
2024
4,993.74
2031

Major Players

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Terumo Corporation
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • Biosensors International Group Ltd
  • Stentys SA
  • Lepu Medical Technology (Beijing) Co Ltd
  • Elixir Medical Corporation
  • Cook Medical Inc
  • Meril Life Sciences Pvt Ltd
  • C. R. Bard Inc
  • SMT (Sahajanand Medical Technologies)

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Bio-engineered Stent Market

Fragmented - Highly competitive market without dominant players


The rise of Bio-engineered Stent Market is transforming interventional cardiology by offering biologically supportive designs that reduce complications. Close to 52% of cardiac procedures now favor these stents for their ability to encourage natural vessel healing and reduce restenosis, setting a new benchmark in post-operative recovery.

Growing Demand Fueled by Safer Outcomes
With 47% of patients experiencing improved vascular healing, the demand for bio-engineered stents continues to climb. Their ability to minimize post-implantation complications, including reduced thrombosis and inflammation, has solidified their reputation as a safer alternative to traditional stents.

Clinical Studies Reinforcing Effectiveness
More than 38% of recently approved bio-engineered stents are supported by clinical trials proving superior healing and minimal late lumen loss. These strong study results are accelerating adoption and influencing treatment protocols in favor of bio-engineered devices.

Adoption Surge Among Specialists
Physicians are increasingly opting for bio-engineered solutions, with 44% of interventional cardiologists preferring them in high-risk or complex cases. The combination of enhanced patient safety and technological innovation is pushing the market toward sustained long-term growth.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Mode of Delivery
    3. Market Snapshot, By Material
    4. Market Snapshot, By Region
  4. Bio-engineered Stent Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing cardiovascular diseases
        2. Advancements in stent technology
        3. Demand for minimally invasive procedures
        4. Aging population
        5. Growing cardiovascular health awareness
      2. Restraints
        1. Stringent regulations
        2. Limited long-term data
        3. Variable patient responses
        4. Reluctance to adopt new tech
        5. Risk of stent complications
      3. Opportunities
        1. Personalized medicine focus
        2. Industry-healthcare collaborations
        3. Biodegradable material innovations
        4. Growth in cardiology training
        5. Combination drug-device therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Bio-engineered Stent Market, By Product, 2021-2031 (USD Million)
      1. Drug-Eluting Stents
      2. Bioabsorbable Stents
      3. Drug-Eluting Balloons
    2. Bio-engineered Stent Market, By Mode of Delivery, 2021-2031 (USD Million)
      1. Balloon-Expandable Stents
      2. Self-Expanding Stents
    3. Bio-engineered Stent Market, By Material, 2021-2031 (USD Million)
      1. Metal-Based
      2. Polymer-Based
    4. Bio-engineered Stent Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott Laboratories
      2. Boston Scientific Corporation
      3. Medtronic plc
      4. Terumo Corporation
      5. B. Braun Melsungen AG
      6. Biotronik SE & Co. KG
      7. MicroPort Scientific Corporation
      8. Biosensors International Group Ltd
      9. Stentys SA
      10. Lepu Medical Technology Co Ltd
      11. Elixir Medical Corporation
      12. Cook Medical Inc
      13. Meril Life Sciences Pvt Ltd
      14. C. R. Bard Inc
      15. SMT (Sahajanand Medical Technologies)
  7. Analyst Views
  8. Future Outlook of the Market